The anti-inflammatory Annexin A1 induces the clearance and degradation of the amyloid-β peptide

Background: The toxicity of amyloid-beta (A beta) peptide present in the brain of Alzheimer's disease (AD) patients is thought to be mediated via the increased secretion of pro-inflammatory mediators, which can lead to neuronal dysfunction and cell death. In addition, we have previously shown that inflammation can affect A beta generation. More recently, we have reported that in vitro administration of the anti-inflammatory mediator Annexin A1 (ANXA1) following an inflammatory challenge suppressed microglial activation and this effect was mediated through formyl peptide receptor-like 1 (FPRL1/FPR2) signalling. The aim of this study was to determine the potential role of ANXA1 in the generation and clearance of A beta. Methods: We first compared ANXA1 protein expression in the brains of AD patients and healthy controls as well as in the 5XFAD model of AD. To determine the role of ANXA1 in the processing of amyloid precursor protein (APP) and the degradation of A beta, N2a neuroblastoma cells were treated with human recombinant ANXA1 or transfected with ANXA1 siRNA. We also investigated the effect of ANXA1 on A beta phagocytosis and microglial activation in BV2 cells treated with synthetic A beta. Results: Our data show that ANXA1 is increased in the brains of AD patients and animal models of AD at early stages. ANXA1 was able to reduce the levels of A beta by increasing its enzymatic degradation by neprilysin in N2a cells and to stimulate A beta phagocytosis by microglia. These effects were mediated through FPRL1 receptors. In addition, ANXA1 inhibited the A beta-stimulated secretion of inflammatory mediators by microglia. Conclusions: These data suggest that ANXA1 plays a pivotal role in A beta clearance and supports the use of ANXA1 as potential pharmacological tool for AD therapeutics.